All In Biotech

Drug Trial Radar · NCT04196491

A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)

A Phase 1, Open-label, Multicenter Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (KarMMa-4)

Last checked: Nov 19, 2026Latest source record: Aug 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

13

Actual

Start

May 27, 2020

Primary completion

Jun 7, 2023

Study completion Jun 7, 2023

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Dec 12, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, phase 1, single arm study intended to determine the optimal target dose and safety of bb2121 in subjects with HR (R-ISS Stage III per IMWG criteria) NDMM. Subjects should have received 3 Cycles of standard induction therapy prior to undergoing leukapheresis procedure to collect autologous mononuclear cells for manufacture of the drug product (bb2121). Following manufacture of the drug product, subjects will receive fourth cycle of induction therapy followed by lymphodepleting therapy with fludarabine and cyclophosphamide prior to bb2121 infusion. Maintenance therapy is recommended for all subjects who have received bb2121 infusion and should be initiated upon adequate bone marrow recovery or from 90-day post-bb2121 infusion, whichever is later.

Conditions

  • Multiple Myeloma

Interventions

  • bb2121Biological

    CAR-T Cell Therapy

  • FludarabineDrug

    Lymphodepleting Chemotherapy

  • CyclophosphamideDrug

    Lymphodepleting Chemotherapy

  • LenalidomideDrug

    Maintenance Therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicity (DLT) ratesTime frame: Up to completion of DLT period after last subject bb2121 infused
  2. Adverse Events (AEs)Time frame: Approximately 2 years after last subject bb2121 infused

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • Local Institution - 119

    Phoenix, Arizona

  • Local Institution - 110

    Los Angeles, California

  • Local Institution - 116

    San Francisco, California

  • Local Institution - 106

    Denver, Colorado

  • Local Institution - 101

    Jacksonville, Florida

  • Local Institution - 113

    Tampa, Florida

  • Local Institution - 108

    Atlanta, Georgia

  • Local Institution - 123

    Atlanta, Georgia

  • Local Institution - 115

    Boston, Massachusetts

  • Local Institution - 122

    Boston, Massachusetts

  • Local Institution - 117

    Hackensack, New Jersey

  • Local Institution - 121

    New York, New York

  • Local Institution - 109

    New York, New York

  • Local Institution - 124

    New York, New York

  • Local Institution - 120

    Charlotte, North Carolina

  • Local Institution - 112

    Portland, Oregon

  • Local Institution - 118

    Philadelphia, Pennsylvania

  • Local Institution - 103

    Nashville, Tennessee

  • Local Institution - 102

    Dallas, Texas

  • Local Institution - 114

    Houston, Texas

  • Local Institution - 104

    Seattle, Washington

  • Local Institution - 107

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.